Enlivex to present Allocetra's therapeutic potential in inflammatory diseases at Israeli BioMed 2025 Conference.
ByAinvest
Tuesday, May 20, 2025 8:20 am ET1min read
ENLV--
Enlivex is a clinical-stage macrophage reprogramming immunotherapy company developing Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. This therapy aims to address chronic and life-threatening inflammatory diseases by resetting non-homeostatic macrophages [1].
The company's presentation will highlight Allocetra™'s therapeutic potential in inflammatory diseases. Preliminary data from a six-month interim readout in moderate knee osteoarthritis showed statistically significant reductions in pain (47%), improvement in joint function (46%), and decrease in stiffness (40%) [1]. Enlivex is currently advancing a broad clinical pipeline with Allocetra™, including multiple Phase I/II trials in osteoarthritis and psoriatic arthritis, with additional readouts expected in 2025 [1].
Enlivex's approach to macrophage reprogramming offers a promising strategy for immune system rebalancing and disease resolution. The company's presentation at the Israeli BioMed 2025 Conference will provide insights into the potential of Allocetra™ in treating inflammatory diseases, positioning Enlivex as a leader in the field of macrophage reprogramming immunotherapy [1].
References:
[1] https://www.marketscreener.com/quote/stock/ENLIVEX-THERAPEUTICS-LTD-56422776/news/Enlivex-Selected-to-Present-at-Israeli-BioMed-2025-Conference-50010352/
Enlivex Therapeutics has been selected to present at the Israeli BioMed 2025 Conference. The company's CEO will deliver a presentation titled "Enlivex—Harnessing the Natural Healing Power of Macrophages to Treat Inflammatory Diseases". Enlivex's Allocetra cell therapy is designed to reset macrophages to their homeostatic state, addressing chronic and life-threatening inflammatory diseases.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) has been selected to present at the upcoming Israeli BioMed 2025 Conference, scheduled from May 21 to 23 in Tel Aviv, Israel. The company's CEO will deliver a presentation titled "Enlivex—Harnessing the Natural Healing Power of Macrophages to Treat Inflammatory Diseases" as part of the session "Personalized Pathways; Genetic and Cellular Based Therapies for Rare and Complex Diseases" [1].Enlivex is a clinical-stage macrophage reprogramming immunotherapy company developing Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. This therapy aims to address chronic and life-threatening inflammatory diseases by resetting non-homeostatic macrophages [1].
The company's presentation will highlight Allocetra™'s therapeutic potential in inflammatory diseases. Preliminary data from a six-month interim readout in moderate knee osteoarthritis showed statistically significant reductions in pain (47%), improvement in joint function (46%), and decrease in stiffness (40%) [1]. Enlivex is currently advancing a broad clinical pipeline with Allocetra™, including multiple Phase I/II trials in osteoarthritis and psoriatic arthritis, with additional readouts expected in 2025 [1].
Enlivex's approach to macrophage reprogramming offers a promising strategy for immune system rebalancing and disease resolution. The company's presentation at the Israeli BioMed 2025 Conference will provide insights into the potential of Allocetra™ in treating inflammatory diseases, positioning Enlivex as a leader in the field of macrophage reprogramming immunotherapy [1].
References:
[1] https://www.marketscreener.com/quote/stock/ENLIVEX-THERAPEUTICS-LTD-56422776/news/Enlivex-Selected-to-Present-at-Israeli-BioMed-2025-Conference-50010352/
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet